Search Results for 'Natalizumab'
5 results found.
Athlone Elan facility not for sale
Pharmaceutical company Elan has put plans to shed its Athlone division on hold, in spite of indications earlier this year that it was planning to separate the Athlone-based Elan Drug Technologies (EDT) from the rest of the company.
Tysabri can improve life quality, says Elan
Athlone-based Elan has claimed that a post-hoc analysis showed that its controversial multiple sclerosis drug Tysabri increases the probability of achieving sustained improvement in physical disability over two years when compared to a placebo.
Good news for Elan as study illustrates Tysabri MS success
Athlone-based drug developer and its US partner, Biogen Idec, last evening hailed success from a study into the effects of their MS drug, Tysabri in repairing damage to the myelin sheath, a key cause of MS.
More upheaval for Elan after summons to appear in US Federal Court
The Monksland-based phamaceutical firm Elan has been summoned to appear in a Federal court in the US after disclosing two cases of a brain disorder related to its trump product, prior to a €605m ($885m) share sale earlier this month.
Elan’s Tysabri lowers Crohn’s hospitalisations
Athlone-based pharmaceutical company, Elan, and its US partner Biogen have announced that their drug Tysabri has been proven to significantly reduce the rate of hospitalisation of patients with moderate-to-severe Crohn’s disease.
